THERAPEUTIC EQUIVALENCE OF ORIGINAL CLOPIDOGREL (PLAVIX) AND ITS GENERIC (EGITROMB). RESULTS OF COMPARATIVE RANDOMIZED CROSS-OVER BLIND STUDY
https://doi.org/10.20996/1819-6446-2011-7-1-19-25
Abstract
Aim. To study therapeutic equivalence (efficacy, safety and tolerability) of original clopidogrel (Plavix) and its generic (Egitromb) in patients of high cardiovascular risk. Material and methods. Thirty one patients with coronary heart disease and indications for clopidogrel therapy were involved into the randomized cross-over blind study. Half of the patients received original clopidogrel (75 mg daily) during the first 2 weeks and then they received generic clopidogrel in the same dose during next 2 weeks. Another half of the patients received the drugs in reverse order. Antiplatelet activity of Plavix and Egitromb was estimated by effects on ADP-induced platelet aggregation initially and after 2 weeks of treatment with each drug. Study blinding was provided by the following approach: doctors of cardiology clinic performed clinical monitoring and drug distribution; coded blood samples for platelet aggregation assessment were studied in independent laboratory of thrombosis; statistical data analysis was performed by biostatistics expert in other research center. Results. 2-week therapy with each drug led to a significant decrease of ADP-induced platelet aggregation which remained low after switching from original drug to generic and vice versa. Aggregation dynamics did not depend on the first administered drug. There were no significant differences between aggregation changes as a result of treatment with original or generic drug. No one adverse event was observed in association with both drugs therapy. Conclusion. Generic drug Egitromb (Egis, Hungary) and original clopidogrel Plavix (Sanofi-Aventis, France) have equivalent antiplatelet effect.
About the Authors
V. V. Yakusevich
Yaroslavl State Medical Academy
Russian Federation
Russian Federation
A. S. Petrochenko
Yaroslavl State Medical Academy
Russian Federation
Russian Federation
V. A. Simonov
Yaroslavl State Medical Academy
Russian Federation
Russian Federation
N. Yu. Levshin
Yaroslavl State Medical Academy
Russian Federation
Russian Federation
A. D. Deev
State Research Center for Preventive Medicine
Russian Federation
Russian Federation
References
1. Collaborative overview of randomized trials of antiplatelet therapy –I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994; 308(6921):81106.
2. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329):71-86.
3. Yusuf S., Zhao F., Mehta S.R. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345(7):494-502.
4. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348(9038):1329-1339.
5. Fox K.A., Mehta S.R., Peters R. et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004; 110(10):1202-8.
6. Steinhubl S.R., Berger P.B., Mann J.T. 3rd et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288(19):2411-20.
7. Anderson J.L., Adams C.D., Antman E.M. et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. Guideline Revision. J Am Coll Cardiol 2007; 50(7):e1-15.
8. National guidelines for antithrombotic therapy in patients with stable manifestations of atherothrombosis. Kardiovaskulyarnaya terapiya i profilaktika 2009; 8(6), prilozhenie 6: 1-28. Russian (Национальные рекомендации по антитромботической терапии у больных со стабильными проявлениями атеротромбоза. Кардиоваскулярная терапия и профилактика 2009; 8(6), приложение 6: 1-28).
9. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010;31(20):2501-55.
10. The use of clopidogrel at ACS. Kardiologiia 2009; 49(12):8-9. Russian (Применение кло-пидогрела при ОКС. Кардиология 2009; 49(12):8-9).
11. Kesselheim A.S., Misono A.S., Lee J.L. et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008; 300(21):2514-26.
12. Verbeeck RK. Bioequivalence, therapeutic equivalence and generic drugs. Acta Clin Belg 2009;64(5):379-83.
13. Yakusevich V.V. Assessment of quality of generic drugs in cardiology: realities and possibilities. Rational Pharmacother Cardiol 2005; 1:13-18. Russian (Якусевич В.В. Оценка качества препаратов-дженериков в кардиологии: реалии и возможности. Рациональная Фармакотерапия в Кардиологии 2005; 1:13-18).
14. Born G.V.R. Quantitative investigation into the aggregation of blood platelets. J Physiol (Lon-don) 1962; 162: 67.
15. Barkagan Z.S., Momot A.P. Diagnosis and controlled therapy of hemostatic disorders. M.: N'yudiamed; 2008. Russian (Баркаган З.С., Момот А.П. Диагностика и контролируемая терапия нарушений гемостаза. М.: Ньюдиамед; 2008).
16. Dankovtseva E.N., Zateyshchikov D.A. Modern Aspects of clopidogrel. Rational Pharmacother Cardiol 2010; 6(2):185-191. Russian (Данковцева Е.Н., Затейщиков Д.А. Со-временные аспекты применения клопидогрела. Рациональная Фармакотерапия в Кардиологии 2010; 6(2):185-191).
17. Dronova E.P., Lopatin Yu.M. Clinical and economic analysis of original and generic forms of clopidogrel in coronary artery disease after endovascular interventions. Kachestvennaya klinicheskaya praktika 2010; 1:1-8. Russian (Дронова Е.П., Лопатин Ю.М. Клинико-экономический анализ оригинальной и генерической форм клопидогрела при ишемической болезни сердца после эндоваскулярных вмешательств. Качественная клиническая практика 2010; 1:1-8).
18. Poponina T.M., Poponina Yu.S., Kapilevich N.A., Efimova E.V. Current approaches to prevention of thrombotic complications in patients with acute coronary syndrome without ST segment elevation ST. Aktualnye voprosy bolezney serdtsa i sosudov 2009; 4: 4-9. Russian (Попонина Т.М., Попонина Ю.С., Капилевич Н.А., Ефимова Е.В. Современные подходы к профилактике тромботических осложнений у больных с острым коронарным синдромом без подъема сегмента ST. Актуальные вопросы болезней сердца и сосудов 2009; 4: 4-9).
19. Shalnova S.A., Martsevich S.Yu. Russian clinical research in cardiology. Yesterday, today and tomorrow. Rational Pharmacother Cardiol 2010; 6(4):434-437. Russian (Шальнова С.А., Марцевич С.Ю. Российские клинические исследования в кардиологии. Вчера, сегодня, завтра. Рациональная Фармакотерапия в Кардиологии 2010; 6(4):434-437).
20. Meshkov A.N. Pharmacogenetics of clopidogrel. Rational Pharmacother Cardiol 2010;6(4):569-572. Russian (Мешков А.Н. Фармакогенетика клопидогрела. Рациональная Фармакотерапия в Кардиологии 2010;6(4):569-572).
21. Sirotkina O.V., Bogdanova E.V., Bogankova N.A. et al. The effectiveness of antiplatelet therapy, clopidogrel in patients with myocardial infarction with ST segment elevation. Kardiovaskulyarnaya terapiya i profilaktika 2009; 8(1):51-5. Russian (Сироткина О.В., Богданова Е.В., Боганькова Н.А. и др. Эффективность антиагрегантной терапии клопидогрелом у пациентов, перенесших инфаркт миокарда с подъемом сегмента ST. Кардиоваскулярная терапия и профилактика 2009; 8(1):51-5).
Review
For citations:
Yakusevich V.V., Petrochenko A.S., Simonov V.A., Levshin N.Yu., Deev A.D. THERAPEUTIC EQUIVALENCE OF ORIGINAL CLOPIDOGREL (PLAVIX) AND ITS GENERIC (EGITROMB). RESULTS OF COMPARATIVE RANDOMIZED CROSS-OVER BLIND STUDY. Rational Pharmacotherapy in Cardiology. 2011;7(1):19-25. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-1-19-25
Views: 1141
Email this article 